Jump to content

SCH-442,416

From Wikipedia, the free encyclopedia
SCH-442,416
Names
Preferred IUPAC name
2-(Furan-2-yl)-7-[3-(4-methoxyphenyl)propyl]-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine
Other names
SCH-442,416
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • InChI=1S/C20H19N7O2/c1-28-14-8-6-13(7-9-14)4-2-10-26-18-15(12-22-26)19-23-17(16-5-3-11-29-16)25-27(19)20(21)24-18/h3,5-9,11-12H,2,4,10H2,1H3,(H2,21,24)checkY
    Key: AEULVFLPCJOBCE-UHFFFAOYSA-NcheckY
  • InChI=1/C20H19N7O2/c1-28-14-8-6-13(7-9-14)4-2-10-26-18-15(12-22-26)19-23-17(16-5-3-11-29-16)25-27(19)20(21)24-18/h3,5-9,11-12H,2,4,10H2,1H3,(H2,21,24)
    Key: AEULVFLPCJOBCE-UHFFFAOYAA
  • n1n3c(nc4c(c3nc1c2occc2)cnn4CCCc5ccc(OC)cc5)N
Properties
C20H19N7O2
Molar mass 389.410
Except where otherwise noted, data are given for materials in theirstandard state(at 25 °C [77 °F], 100 kPa).

SCH-442,416is a highly selectiveadenosineA2asubtype receptorantagonist.It is widely used in its11Cradiolabelledform to map the distribution of A2areceptors in the brain, where they are mainly found in thestriatum,nucleus accumbens,andolfactory tubercle.[1]Given its distribution in the brain, A2areceptors have been investigated for the treatment of various neurological disorders, and SCH-442,416 has shown promise in treatment ofdepression,[2]Parkinson's disease,[3]andcatalepsy.[4]

References[edit]

  1. ^Moresco RM, Todde S, Belloli S, Simonelli P, Panzacchi A, Rigamonti M, et al. (April 2005). "In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416".European Journal of Nuclear Medicine and Molecular Imaging.32(4): 405–13.doi:10.1007/s00259-004-1688-5.PMID15549298.S2CID20909406.
  2. ^El Yacoubi M, Costentin J, Vaugeois JM (December 2003). "Adenosine A2A receptors and depression".Neurology.61(11 Suppl 6): S82-7.doi:10.1212/01.wnl.0000095220.87550.f6.PMID14663017.S2CID36219448.
  3. ^Matsuya T, Takuma K, Sato K, Asai M, Murakami Y, Miyoshi S, et al. (March 2007)."Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model".Journal of Pharmacological Sciences.103(3): 329–32.doi:10.1254/jphs.scz070058.PMID17341841.
  4. ^Mihara T, Noda A, Arai H, Mihara K, Iwashita A, Murakami Y, et al. (July 2008)."Brain adenosine A2A receptor occupancy by a novel A1/A2A receptor antagonist, ASP5854, in rhesus monkeys: relationship to anticataleptic effect".Journal of Nuclear Medicine.49(7): 1183–8.doi:10.2967/jnumed.108.051474.PMID18552135.

External links[edit]